Results 151 to 160 of about 2,674,072 (303)

Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT‐1 and SURMOUNT‐2 Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Obesity affects over 800 million people globally and is associated with complications including cardiovascular disease and type 2 diabetes (T2D). Early response to weight loss interventions may help optimize achievement of individual treatment goals.
Alexander Kokkinos, Tina Thethi, Clare J. Lee, Lisa M. Neff, Adam Stefanski, Dachuang Cao, Angel Rodriguez, Amy Bartee   +7 more
wiley   +1 more source

ABCC8-associated with maturity-onset diabetes in a young woman: clinical features and genetic analysis

Сибирский научный медицинский журнал
ABCC8-MODY is caused by variants in the ATP-binding cassette transporter subfamily C member 8 (ABCC8) gene, which encodes sulfonylurea receptor 1 (SUR1), a subunit of the ATP-sensitive potassium channel (K-ATP) found in β-cell membranes.
O. D. Rymar, S. V. Mustafina, A. K. Ovsyannikova, E. V. Shakhtshneider, D. E. Ivanoshchuk, E. D. Ruzaeva, Yu. A. Dolinskaya, V. A. Stoyakina, A. A. Radionova   +8 more
doaj   +1 more source

Glibenclamide, a Sur1-Trpm4 antagonist, does not improve outcome after collagenase-induced intracerebral hemorrhage.

PLoS ONE, 2019
The sulfonylurea 1 transient receptor potential melastatin 4 (Sur1-Trpm4) receptor is selectively expressed after intracerebral hemorrhage (ICH). This upregulation contributes to increases in intracellular sodium.
Cassandra M Wilkinson, Paul S Brar, Celine J Balay, Frederick Colbourne   +3 more
doaj   +1 more source

One Week Exposure to a Somatostatin Receptor 2 Antagonist (SSTR2a) Enhances Glucagon Counterregulation to Insulin‐Induced Hypoglycaemia and Does Not Worsen Glycemia in a Male Rat Model of Insulin‐Requiring Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Introduction Administration of a somatostatin receptor 2 antagonist (SSTR2a) increases glucagon responsiveness to hypoglycaemia in insulin‐treated type 2 diabetes (T2D), but the durability of this effect and the impact of repeated SSTR2a dosing on overall glycaemia in T2D are unclear.
Ninoschka C. D'Souza, Emily G. Hoffman, Sara C. Atherley, Sabrina Champsi, Nadia Aleali, Richard T. Liggins, Owen Chan, Michael C. Riddell   +7 more
wiley   +1 more source

Prescribing Trajectories in Type 2 Diabetes in the United States, 2019–2024

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Importance Clinical guidelines for type 2 diabetes (T2D) provide population‐level recommendations, but real‐world treatment patterns evolve dynamically and vary across patients. Understanding longitudinal prescribing trajectories may reveal heterogeneity in care not captured by cross‐sectional analyses.
Tobias S. Lux, Dongkun Lee, Jeff M. Phillips, Julio C. Facelli, Daniel C. Malone, Matthew Wahl, Deepika Reddy, Farrant Sakaguchi, Ramkiran Gouripeddi, Alexander S. Millar, Matthew J. O'Brien, Joshua S. Choi, Jittrapol Sutejitsiri, Kensaku Kawamoto, Polina V. Kukhareva   +14 more
wiley   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Major Adverse Liver Outcomes in People With Type 2 Diabetes and Metabolic Dysfunction‐Associated Steatotic Liver Disease

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Treatment options for metabolic dysfunction‐associated steatotic liver disease (MASLD) are limited. While glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors improve cardiovascular outcomes, comparative effectiveness on liver‐related outcomes remains unclear.
Gregor A. Maier, Ramon A. Hofmann, Michael Roden, Wolfgang Rathmann, Oliver Kuss   +4 more
wiley   +1 more source

Pharmaco-topology of Sulfonylurea Receptors [PDF]

Journal of Biological Chemistry, 2000
Andrey P. Babenko, Gabriela Gonzalez, Joseph Bryan   +2 more
openaire   +1 more source

A Four‐Week Treatment With Dapagliflozin Is Associated With a Reduction in Insulin‐Stimulated Renal Cortical Glucose Uptake: A Post Hoc Analysis From a Pilot Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Introduction and Objective Treatment with sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2i) reduces the risk of both cardiovascular and renal outcomes in type 2 diabetes (T2D). The specific mechanism by which this happens has not yet been clarified.
Shawn Gugliandolo, Cassandra Morciano, Andrea Guarneri, Gian Pio Sorice, Marta Giaccari, Luigi Cappannoli, Umberto Capece, Amelia Splendore, Adriana Avolio, Lorenzo Diego Greco, Patricia Iozzo, Rossana Moroni, Alfredo Pontecorvi, Maria Lucia Calcagni, Francesco Burzotta, Domenico D'Amario, Filippo Crea, Lucia Leccisotti, Francesca Cinti   +18 more
wiley   +1 more source

Cholesterol accumulation in monocytes is associated with the severity of diabetic complications and the efficacy of glycemic control interventions in patients with type 2 diabetes

Journal of Diabetes Investigation, EarlyView.
This study reveals that monocyte cholesterol accumulation correlates with the severity of diabetic complications and predicts post‐discharge glycemic deterioration. These findings suggest that monocytic cholesterol serves as a novel translational biomarker reflecting ‘metabolic memory’ and therapeutic resistance in patients with type 2 diabetes ...
Hideyuki Okuma, Takahiro Tsutsumi, Asako Miyazaki, Kyoichiro Tsuchiya   +3 more
wiley   +1 more source

Dulaglutide versus empagliflozin as add-on therapy to metformin and sulfonylurea in type 2 diabetes: a randomized pilot study with exploratory metabolomic and microbiome analyses

Frontiers in Endocrinology
In patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and sulfonylurea, evidence directly comparing glucagon-like peptide-1 receptor agonists and sodium–glucose cotransporter 2 inhibitors as add-on therapy is limited ...
Ji Eun Jun, Da-Hee Oh, Da-Hee Oh, In-Kyung Jeong, Hyun Jin Ryu, You-Cheol Hwang, Kyu Jeung Ahn, Ho Yeon Chung, Kwang Pyo Kim   +8 more
doaj   +1 more source